Business Segment Information (Tables)

9 Months Ended

Sep. 28, 2013

Business Segments

Schedule of Segment Reporting Information, by Segment [Table Text Block]

				Three Months Ended						Nine Months Ended
			September 28,			September 29,			September 28,			September 29,
(In millions)				2013			2012			2013			2012
Revenues
	Analytical Technologies			$	996.6		$	986.5		$	2,980.9		$	2,938.9
	Specialty Diagnostics				759.2			706.7			2,358.4			2,170.5
	Laboratory Products and Services				1,582.1			1,526.3			4,709.6			4,537.1
	Eliminations				(146.1)			(133.8)			(425.5)			(395.9)
		Consolidated revenues			3,191.8			3,085.7			9,623.4			9,250.6
Segment Income
	Analytical Technologies (a)				180.4			186.1			534.4			533.9
	Specialty Diagnostics (a)				203.7			170.0			642.3			556.2
	Laboratory Products and Services (a)				235.3			219.6			681.6			652.2
		Subtotal reportable segments (a)			619.4			575.7			1,858.3			1,742.3
	Cost of revenues charges				(0.9)			(3.1)			(27.2)			(42.5)
	Selling, general and administrative charges, net				(24.0)			(19.0)			(47.9)			(13.1)
	Restructuring and other costs, net				(11.4)			(15.2)			(54.4)			(51.7)
	Amortization of acquisition-related intangible assets				(191.0)			(186.2)			(574.2)			(553.5)
		Consolidated operating income			392.1			352.2			1,154.6			1,081.5
	Other expense, net (b)				(73.1)			(55.8)			(212.7)			(155.6)
	Income from continuing operations before income taxes			$	319.0		$	296.4		$	941.9		$	925.9
Depreciation
	Analytical Technologies			$	15.9		$	15.1		$	46.2		$	47.3
	Specialty Diagnostics				18.2			18.2			54.7			53.8
	Laboratory Products and Services				25.3			25.7			75.5			74.7
		Consolidated depreciation		$	59.4		$	59.0		$	176.4		$	175.8
(a)	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.
(b)	The company does not allocate other expense, net to its segments.

Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]

				Three Months Ended						Nine Months Ended
			September 28,			September 29,			September 28,			September 29,
(In millions)				2013			2012			2013			2012
Revenues
	Analytical Technologies			$	996.6		$	986.5		$	2,980.9		$	2,938.9
	Specialty Diagnostics				759.2			706.7			2,358.4			2,170.5
	Laboratory Products and Services				1,582.1			1,526.3			4,709.6			4,537.1
	Eliminations				(146.1)			(133.8)			(425.5)			(395.9)
		Consolidated revenues			3,191.8			3,085.7			9,623.4			9,250.6
Segment Income
	Analytical Technologies (a)				180.4			186.1			534.4			533.9
	Specialty Diagnostics (a)				203.7			170.0			642.3			556.2
	Laboratory Products and Services (a)				235.3			219.6			681.6			652.2
		Subtotal reportable segments (a)			619.4			575.7			1,858.3			1,742.3
	Cost of revenues charges				(0.9)			(3.1)			(27.2)			(42.5)
	Selling, general and administrative charges, net				(24.0)			(19.0)			(47.9)			(13.1)
	Restructuring and other costs, net				(11.4)			(15.2)			(54.4)			(51.7)
	Amortization of acquisition-related intangible assets				(191.0)			(186.2)			(574.2)			(553.5)
		Consolidated operating income			392.1			352.2			1,154.6			1,081.5
	Other expense, net (b)				(73.1)			(55.8)			(212.7)			(155.6)
	Income from continuing operations before income taxes			$	319.0		$	296.4		$	941.9		$	925.9
Depreciation
	Analytical Technologies			$	15.9		$	15.1		$	46.2		$	47.3
	Specialty Diagnostics				18.2			18.2			54.7			53.8
	Laboratory Products and Services				25.3			25.7			75.5			74.7
		Consolidated depreciation		$	59.4		$	59.0		$	176.4		$	175.8
(a)	Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles.
(b)	The company does not allocate other expense, net to its segments.